Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study
| dc.contributor.author | Florentin, M. | en |
| dc.contributor.author | Liberopoulos, E. N. | en |
| dc.contributor.author | Filippatos, T. D. | en |
| dc.contributor.author | Kostara, C. | en |
| dc.contributor.author | Tselepis, A. | en |
| dc.contributor.author | Mikhailidis, D. P. | en |
| dc.contributor.author | Elisaf, M. | en |
| dc.date.accessioned | 2015-11-24T16:57:07Z | |
| dc.date.available | 2015-11-24T16:57:07Z | |
| dc.identifier.issn | 1465-6566 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/10538 | |
| dc.rights | Default Licence | - |
| dc.subject | body weight | en |
| dc.subject | fenofibrate | en |
| dc.subject | high-density lipoprotein cholesterol | en |
| dc.subject | rimonabant | en |
| dc.subject | triglycerides | en |
| dc.subject | waist circumference | en |
| dc.subject | high-density-lipoprotein | en |
| dc.subject | cannabinoid-1 receptor blocker | en |
| dc.subject | low-fat diet | en |
| dc.subject | metabolic syndrome | en |
| dc.subject | cardiovascular risk | en |
| dc.subject | cholesterol levels | en |
| dc.subject | obese-patients | en |
| dc.subject | weight-reduction | en |
| dc.subject | orlistat | en |
| dc.subject | kinetics | en |
| dc.title | Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study | en |
| heal.abstract | Objective: To assess the effect of rimonabant, micronised fenofibrate and their combination on anthropometric and metabolic parameters in overweight/obese patients with dyslipidaemia. Methods: All patients (n = 30) received a hypocaloric diet (similar to 600 kcal/day deficit) and were randomly allocated to receive open-label rimonabant (R) 20 mg/day (n = 10), micronised fenofibrate (F) 200 mg/day (n = 10) or rimonabant 20 mg/day plus fenofibrate 200 mg/day (RF) (n = 10). Anthropometric and metabolic parameters were assessed at baseline and 3 months after treatment initiation. Results: Compared with baseline similar significant reductions in body weight, body mass index and waist circumference were observed in the R (-6, -5 and -5%, respectively; p < 0.01) and RF group (-5% for all, p < 0.05), while improvements in these parameters were smaller in the F group (-2, -2.5 and -2%, respectively; p < 0.05). Triglycerides were reduced by 18% in the R group (p = NS), by 39% in the F group (p < 0.001) and by 46% in the RF group (p < 0.05). Importantly, combination treatment resulted in a 42% increase in high-density lipoprotein cholesterol (HDL-C) levels (p < 0.05), while HDL-C was not significantly altered in the two monotherapy groups. Subsequently, a more pronounced increase in apolipoprotein A-I (ApoA-I) levels (+25%) was observed in the RF group compared with changes in both monotherapy groups (p < 0.0001 vs R and p < 0.005 vs F group). Low-density lipoprotein cholesterol (LDL-C) levels were not significantly altered in any group. Apolipoprotein B (apoB) levels were reduced in all groups and this reduction was significantly more pronounced in the RF group (p < 0.05 vs baseline as well as p < 0.005 and p < 0.01 for RF vs R and F groups, respectively). ApoB/apoA-I ratio decreased by 3% with R (p = NS), by 18% with F (p < 0.05) and by 40% with RF treatment (p < 0.01). Total cholesterol to HDL-C ratio decreased by 20% with F (p < 0.0001) and by 33% with RF therapy (p < 0.005), while it was not significantly altered in R group. Conclusion: The combination of rimonabant and fenofibrate may further improve metabolic parameters in overweight/obese patients with dyslipidaemia compared with each monotherapy. This improvement is particularly pronounced for HDL-C levels. | en |
| heal.access | campus | - |
| heal.fullTextAvailability | TRUE | - |
| heal.identifier.primary | Doi 10.1517/14656560802469777 | - |
| heal.identifier.secondary | <Go to ISI>://000261020400002 | - |
| heal.identifier.secondary | http://informahealthcare.com/doi/abs/10.1517/14656566.9.16.2741 | - |
| heal.journalName | Expert Opinion on Pharmacotherapy | en |
| heal.journalType | peer reviewed | - |
| heal.language | en | - |
| heal.publicationDate | 2008 | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείας | el |
| heal.type | journalArticle | - |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: